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DOI 10.1186/s12881-015-0160-7RESEARCH ARTICLE Open AccessImpact of PTBP1 rs11085226 on glucose-stimulated
insulin release in adult Danes
Tue H Hansen1*, Henrik Vestergaard1, Torben Jørgensen2,3, Marit Eika Jørgensen4, Torsten Lauritzen5,
Ivan Brandslund6,7, Cramer Christensen8, Oluf Pedersen1, Torben Hansen1,9 and Anette P Gjesing1Abstract
Background: The variant rs11085226 (G) within the gene encoding polypyrimidine tract binding protein 1 (PTBP1)
was reported to associate with reduced insulin release determined by an oral glucose tolerance test (OGTT) as well
as an intravenous glucose tolerance test (IVGTT). The aim of the present study was to validate the association of the
rs11085226 G-allele of PTBP1 with previously investigated OGTT- and IVGTT-derived diabetes-related metabolic
quantitative phenotypes, to conduct exploratory analyses of additional measures of beta-cell function, and to further
investigate a potential association with type 2 diabetes.
Methods: PTBP1 rs11085226 was genotyped in 20,911 individuals of Danish Caucasian ethnicity ascertained from 9
study samples. Case control analysis was performed on 5,634 type 2 diabetic patients and 11,319 individuals having
a normal fasting glucose level as well as 4,641 glucose tolerant controls, respectively. Quantitative trait analyses
were performed in up to 13,605 individuals subjected to an OGTT or blood samples obtained after an overnight
fast, as well as in 596 individuals subjected to an IVGTT.
Results: Analyses of fasting and OGTT-derived quantitative traits did not show any significant associations with the PTBP1
rs11085226 variant. Meta-analysis of IVGTT-derived quantitative traits showed a nominally significant association between
the variant and reduced beta-cell responsiveness to glucose (β= −0.1 mmol · kg−1 · min−1; 95% CI: −0.200.20 – −0.024;
P= 0.01) assuming a dominant model of inheritance, but failed to replicate a previously reported association with area
under the curve (AUC) for insulin. Case control analysis did not show an association of the PTBP1 rs11085226 variant with
type 2 diabetes.
Conclusions: Despite failure to replicate the previously reported associations of PTBP1 rs11085226 with OGTT- and
IVGTT-derived measures of beta-cell function, we did find a nominally significant association with reduced beta-cell
responsiveness to glucose during an IVGTT, a trait not previously investigated, leaving the potential influence of this variant
in PTBP1 on glucose stimulated insulin release open for further investigation. However, the present study does not support
the hypothesis that the variant confers risk of type 2 diabetes.
Keywords: Polypyrimidine tract binding protein 1, Type 2 diabetes, Beta-cell function, Genetics, Insulin releaseBackground
The global prevalence of type 2 diabetes (T2D) is reach-
ing pandemic proportions with an alarming estimate of
439 million affected individuals world-wide (equal to
7.7% of the world’s population) by the year 2030 [1]. It is
well established, that the hyperglycemia observed in
T2D arises due to a combination of peripheral insulin* Correspondence: tuehhansen@sund.ku.dk
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unless otherwise stated.resistance and impaired pancreatic beta-cell function
and consequently reduced insulin secretion [2,3]. T2D is
a heritable [4-6], complex metabolic disorder involving
several molecular pathways with currently 90 known
genetic susceptibility loci, most of which have been iden-
tified in recent years by large-scale genome-wide associ-
ation studies (GWAS) [7]. However, despite recent
advances in the understanding of the genetic mecha-
nisms underlying T2D, a substantial part of the heritabil-
ity (~80-90%) remains unexplained [8].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ported a nominal association between reduced glucose stim-
ulated insulin release and the rs11085226 G-allele of the
gene encoding polypyrimidine tract binding protein 1
(PTBP1). PTBP1 is a 57 kDa protein consisting of four RNA
recognition motifs [10]. It is involved in pre-mRNA and
mRNA metabolism as a regulator of alternative splicing,
polyadenylation, mRNA stability and initiation of translation
[11-13]. It facilitates the biosynthesis and secretion of insulin
by binding the pyrimidine rich tract of the 3′-untranslated
region of insulin mRNA [14] and other mRNA molecules
encoding secretory proteins present in insulin granules of
the pancreatic beta-cell [15-17], thus increasing mRNA sta-
bility and translation [12,18-20]. Disruption of PTBP1 func-
tion, either by siRNA mediated inhibition or mutation of the
PTB binding site, results in insulin mRNA destabilization
and lower insulin contents [14,15]. Similarly, depletion of
PTB levels by microRNA mediated inhibition of PTB-
mRNA translation, lowers insulin biosynthesis rates [21].
Also, nuclear retention of PTBP1 has been proposed as a
contributing factor in the impairment of rapid glucose-
stimulated insulin secretion observed in type 2 diabetic indi-
viduals [22]. Variation in the PTBP1 locus may thus affect
insulin secretion and could potentially be associated with a
type 2 diabetic phenotype.
Assuming a dominant model of inheritance, Heni et al.
[9] found that the minor G-allele of PTBP1 rs11085226 was
nominally associated with a lower insulinogenic index (IGI)
and lower corrected insulin response (CIR) in 1,502 healthy
individuals of German ethnicity subjected to an oral glucose
tolerance test (OGTT). In a subset of participants, the vari-
ant was also nominally associated with lower insulin levels
within the first ten minutes of an intravenous glucose toler-
ance test (IVGTT). Three additional tag SNPs (rs351974,
rs736926 and rs123698) were examined showing no associ-
ation with OGTT derived measures and only the rs351974
was associated with decreased insulin secretion measured as
the AUC for insulin within the first 10 minutes of an
IVGTT. The authors also noted that the rs11085226 variant
was nominally associated with reduced homeostatic model
assessment of beta-cell function (P = .01815) in the publicly
available Meta-Analyses of Glucose and Insulin-related traits
(MAGIC) consortium dataset [23].
Thus, the aim of the present study was to validate the
association of PTBP1 rs11085226 with previously inves-
tigated OGTT- and IVGTT-derived diabetes-related
metabolic quantitative phenotypes, to conduct explora-
tory analyses of additional measures of beta-cell func-
tion, and to further investigate the association with T2D.
Methods
Subjects and genotyping
Using the KASPTM di-allelic discrimination (LGC Genom-
ics, Herts, UK), the PTBP1 rs11085226 was successfullygenotyped in 20,821 individuals, ascertained from 9 study
groups (Additional file 1: Table A). Discordance between
1,361 random duplicate samples was 0.0%, and the geno-
typing success rate was 98.1%. The examined marker
obeyed Hardy-Weinberg equilibrium (P = 0.5) with a
minor allele frequency (MAF) of 0.084 (95% CI 0.082 –
0.087) which is close to that reported by the International
HapMap project (release 24, November 2010, http://www.
hapmap.org) [24] for a population of northern and western
European origin (MAF = 0.092; 95% CI 0.055 – 0.131).
Case–control analyses were performed with 5,634 type 2
diabetic individuals (study groups 1–6) and non-diabetic
controls consisting of either 4,641 glucose-tolerant (as de-
termined by an OGTT) individuals (study groups 1 & 4),
or 11,319 individuals having a normal fasting glucose level
(excluding impaired glucose tolerance where OGTT data
is available; study groups 1–4,6) (Additional file 1: Table B).
Analysis of diabetes-related quantitative traits was per-
formed on 13,605 non-diabetic individuals (study groups
1,2,4,6,7), of which 6,183 (study groups 1,4,7) were sub-
jected to an OGTT, and 596 non-diabetic participants
(study groups 6, 11) subjected to an IVGTT (Additional
file 1: Table B). All participants were Danish Caucasians by
self-report and written informed consent was obtained
from all subjects prior to participation. Glucose tolerance
status was determined by an OGTT and T2D was defined
according to the 1999 World Health Organization criteria
[25]. All studies were approved by the Ethical Committee
for the County of Copenhagen (study groups 1–4,7-9) or
the Region of Southern Denmark (study groups 5 and 6),
the Danish Data Protection Agency and conducted in ac-
cordance with the Helsinki Declaration. .
Anthropometrics
In all study groups, body weight and height were mea-
sured in light indoor clothes and without shoes. BMI
was defined as weight in kilograms divided by height in
meters squared (kg/m2).
OGTT
After a 12-h overnight fast, participants in study groups 1
and 4 underwent a standard 75 g OGTT. Serum insulin
and plasma glucose was measured at 0, 30 and 120 minutes.
Serum insulin levels (excluding des-31,32 and intact pro-
insulin) were measured using the AutoDELFIA insulin kit
(Perkin-Elmer, Wallac, Turku, Finland). Plasma glucose
was analyzed using a glucose oxidase method (Granutest;
Merck, Darmstadt, Germany) [26].
IVGTT
Youth92
Following a 12-h overnight fast, individuals underwent an
IVGTT. After insertion of a cannula into the antecubital
vein each subject rested in a quiet room for at least
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and plasma glucose were taken in duplicate with 5-min in-
tervals. Glucose was injected intravenously in the contra-
lateral antecubital vein over a period of 60 s (0.3 g/kg body
weight of 50% glucose). At 20 min after the glucose injec-
tion, a bolus of 3 mg tolbutamide/kg body weight (Rasti-
non, Hoechst, Germany) was injected over 5 s to elicit a
secondary pancreatic beta-cell response. Venous blood was
sampled at 2, 4, 8, 19, 22, 30, 40, 50, 70, 90, and 180 min,
after glucose injection for measurements of plasma glu-
cose, serum insulin and serum C-peptide. All IVGTTs were
done by the same investigator. Plasma concentration of
glucose (Diagnostica, Boehringer Mannheim GmbH,
Mannheim, Germany) was analyzed using standardized
methods. Serum insulin levels (excluding des-31,32 and in-
tact proinsulin) were measured by enzyme-linked im-
munosorbent assay (ELISA), applying the Dako insulin kit
with overnight incubation (code No. K6219; Dako Diag-
nostics Ltd., Ely, United Kingdom) [27]. The concentration
of C-peptide was determined by radioimmunoassay [28]
using the polyclonal antibody M1230 [29,30].
Family studies
After a 12-hour overnight fast, participants were subjected to
an IVGTT in which glucose min (0.3 g/kg body weight of
50% glucose) was injected in the contralateral antecubital
vein over a period of 1 minute. At 20 min, a bolus of 3 mg
tolbutamide/kg body weight (Orinase, Upjohn, Kalamazoo,
MI, USA) was injected over 5 seconds to elicit a secondary
pancreatic beta-cell response. Venous blood samples were
drawn in triplicate at 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 22,
23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 140,
160, and 180 minutes for analysis of plasma concentration of
glucose and serum insulin. The plasma glucose concentra-
tion was analyzed by a glucose oxidase method (Granutest,
Merck, Darmstadt, Germany). Serum insulin was determined
by ELISA excluding des-31,32 and intact proinsulin [27].
Calculations and statistical analyses
Statistical analyses were performed using RGui v3.0.1
(http://www.r-project.org/) except the family study sample
which was analyzed using the SOLAR software package
(http://solar.txbiomedgenetics.org/) taking family relation
into account through variance component analysis of mul-
tipoint relative-pair identity-by-descent probabilities [31].
Hardy-Weinberg equilibrium was tested using continuity
corrected χ2 test. For all analyses, an uncorrected two-
tailed P-value <0.05 was considered significant. Individuals
with unknown diabetes status were excluded from the
analyses.
Case control analysis for T2D
To examine differences in genotype distributions be-
tween affected and unaffected subjects (either glucosetolerant or having a normal fasting glucose level, cat-
egories non-mutually exclusive) logistic regression was
applied, adjusting for sex, age, BMI, and study group.
Analyses were conducted assuming either an additive or
dominant inheritance model. Differences in allele fre-
quency were examined using Fisher’s exact test.
Quantitative trait analyses – Fasting/OGTT
Insulinogenic index (IGI) was calculated as (Ins30− Ins0)/
Glu30− Glu0) [32]. Corrected insulin response (CIR) was
calculated as (100 · Ins30)/(Glu30 · [Glu30 – 3.89]) [33]. The
homeostatic model assessment of beta-cell function
(HOMA-B) and insulin resistance (HOMA-IR) was calcu-
lated as (20 · Ins0)/(Glu0 – 3.5) and (Ins0 · Glu0)/22.5 re-
spectively [34]. BIGTT-AIR was calculated according to
Hansen et al. [35], insulin sensitivity (ISI) was calculated
according to Matsuda et al. [36] and the disposition index
(DI) as ISI · IGI. Areas under the curve (AUC) were calcu-
lated using the trapezoidal method and incremental values
represents the expression above basal values. A general lin-
ear model was used to test quantitative traits for differ-
ences between genotype groups, excluding individuals with
known or screen detected diabetes. Analyses were per-
formed for an additive and dominant model with adjust-
ment for sex, age, study group and BMI with and without
adjustment for insulin resistance (HOMA-IR). In a subset
of individuals (study group 1) the analysis was adjusted for
sex, age, BMI and insulin sensitivity (Matsuda). Analyses of
DI were adjusted for age, sex, and BMI only. Logarithmic
transformation was applied where appropriate.
Quantitative trait analyses – IVGTT
Insulin sensitivity index and glucose effectiveness were
calculated using the Bergman MINIMOD computer pro-
gram developed specifically for the combined intravenous
glucose and tolbutamide tolerance test [37-41]. Acute
phase insulin (AIR) and C-peptide (ACR) responses were
calculated by means of the trapezoidal rule as the incre-
mental values (areas under the curve when expressed
above basal values) from 0 to 8 min. Insulin secretion rate
(ISR) was estimated from measured serum C-peptide con-
centrations applying the ISEC software to perform decon-
volution [42]. The beta-cell responsiveness to glucose was
established by using the linear relationship between ISR
and glucose in all participants as an index of beta cell re-
sponse to glucose (increase in ISR per unit increase in
plasma glucose) [43]. The disposition index (DI) was calcu-
lated as the product of insulin sensitivity index and first
phase insulin responses (0–8 min) [44,45]. Meta-analyses
were performed using effect size estimates and SE derived
from a linear regression analysis, assuming either an addi-
tive or dominant inheritance model with adjustment for
age, sex, BMI and insulin sensitivity (Bergman MINI-
MOD). Analyses of DI were adjusted for age, sex, and BMI
Hansen et al. BMC Medical Genetics  (2015) 16:17 Page 4 of 9only. Traits were log transformed where appropriate. In
the meta-analyses both fixed effect (weight of studies esti-
mated using inverse variance) and random effect (weight
of studies estimated using DerSimonian-Laird method)
[46] were reported.
Results
Case control analysis for T2D
Association analysis in 5,634 T2D individuals and 4,641
glucose-tolerant control subjects showed no significant
difference in genotype distribution or allele frequency
between affected and unaffected individuals for neither
an additive or dominant model of inheritance (Table 1).
Expanding the control group to 11,319 individuals by in-
cluding all individuals having normal fasting glycaemia,
did not reveal any significant association across inherit-
ance models (Additional file 1: Table C). To address the
issue of collinearity arising from inclusion of study
groups with T2D individuals or controls only, further
analyses in a subset of studies with both outcomes were
performed, showing no significant association between
the rs11085226 variant and T2D (Additional file 1:
Tables D and E).
Quantitative trait analyses – Fasting/OGTT
Regression analysis of rs11085226 in up to 13,605 non-
diabetic individuals, adjusted for age, sex, BMI and study
group, with or without adjustment for insulin resistance
(HOMA-IR), and assuming either an additive or dominant
model of inheritance, showed no significant association
with fasting or OGTT-derived variables of glucose homeo-
stasis and beta-cell function (Table 2). In a subset of 5,031
individuals (study group 1) adjustment for insulin sensitiv-
ity (Matsuda) in addition to gender, age, and BMI did not
reveal any significant associations for neither an additive
nor a dominant model (Additional file 1: Table F).
Quantitative trait analyses – IVGTT
In a fixed-effect meta-analysis of the Family- and Youth
92 study (study groups 8 & 9) including IVGTT-derivedTable 1 Association analysis of type 2 diabetes and PTBP1 rs1
glucose-tolerant control subjects
Genotype distribution Additiv
NGT T2D OR
N 4641 5634 1.13 (0.8
AA 3874 (83.5) 4741 (84.1)
AG 739 (15.9) 848 (15.1)
GG 28 (0.6) 45 (0.8)
MAF 8.6 (8.0 – 9.1) 8.3 (7.8 – 8.8) 0.97 (0.8
Data are number of subjects in each genotype group (% of each group) and MAF in
calculated using logistic regression with adjustment for sex, age, BMI and study gro
Fisher’s exact test (b). Analyses were conducted for men and women combined ass
tolerance. T2D: Type 2 diabetes.traits in 596 individuals, the G-allele was significantly as-
sociated with lower beta-cell responsiveness to glucose
(β-value: −0.11 mmol · kg−1 · min−1; 95% CI: −0.20 –
-0.025; P = 0.01) when assuming a dominant model of
inheritance and adjusting for age, sex, BMI and insulin
sensitivity (Table 3). Despite the absence of any signifi-
cant between-study heterogeneity (I2 = 47.3%, P = 0.17),
only a P-value of 0.06 was found when using a random-
effect analysis (Figure 1). Assuming an additive model of
inheritance neither a fixed nor random effect analysis
showed any significant associations with any of the
IVGTT-derived traits (Table 3).
Discussion
In the present study, we tried to replicate the previ-
ously reported association of PTBP1 rs11085226 with
reduced glucose stimulated insulin release in a Danish
Caucasian population and to complement with an in-
vestigation of measures of beta-cell function and the
potential association to T2D. Adjusting for the same
covariates as in the original study, we were unable to
replicate the reported association with OGTT-derived
measures of insulin release. Interestingly, in the
MAGIC consortium data released in May 2014, the
rs11085226 variant was neither associated with DI
(P = 0.71), ISI adjusted CIR (P = 0.86) nor any other
OGTT-derived indices of glucose-stimulated insulin
secretion in up to 5,318 non-diabetic participants from
9 cohorts [47].
In the meta-analysis of IVGTT-derived traits, we did
not find an association with AUC insulin, which was
previously reported to be significantly reduced in car-
riers of the rs11085226 minor allele. We did find,
however, that the variant is associated with reduced
beta-cell responsiveness to glucose which represents
the increase in insulin release rate per unit increase in
plasma glucose. Interestingly, this measure of acute
phase insulin release has previously been found to be
reduced by a factor 3 in seven T2D patients of Caucasian
ethnicity [43]. In the same study, the reduced beta-cell1085226 in 5,634 type 2 diabetes patients and 4,641
e model Dominant model
P OR P
8 - 1.46) 0.33a 1.14 (0.87 - 1.49) 0.33a
8 - 1.07) 0.55b
% (95% CI). OR (95% CI) and P-values for genotype distribution were
up (a). OR (95% CI) and P-values for allele frequency were calculated using
uming either an additive or dominant inheritance model. NGT: Normal glucose
Table 2 Quantitative metabolic traits in up to 13,605 non-diabetic Danish Caucasian subjects stratified according to
genotype
n AA AG GG Padd Pdom
Glycated hemoglobin
HbA1c (%)¤ 13251 (11071/2099/81) 5.61 (0.41) 5.60 (0.41) 5.56 (0.39) 0.14 (0.15) 0.19 (0.22)
Plasma glucose
Glu0 (mmol/l) 13599 (11378/2139/82) 5.47 (0.53) 5.48 (0.51) 5.49 (0.55) 0.26 (0.28) 0.23 (0.26)
Glu30 (mmol/l)
¤ 5522 (4631/860/31) 8.58 (1.70) 8.52 (1.74) 8.66 (1.51) 0.85 (0.76) 0.95 (0.61)
Glu120 (mmol/l)
¤ 6155 (5180/942/33) 5.96 (1.55) 5.93 (1.50) 5.90 (1.62) 0.90 (0.58) 0.90 (0.60)
AUCGlu (mmol/l·min)
¤ 5510 (4621/858/31) 864.70 (144.86) 863.19 (138.62) 862.84 (121.30) 0.99 (0.65) 0.97 (0.56)
Serum insulin
Ins0 (pmol/l)
¤ 8944 (7504/1388/52) 40.87 (26.56) 40.17 (25.43) 39.84 (24.64) 0.43 (0.29) 0.41 (0.32)
Ins30 (pmol/l)
¤ 5342 (4468/844/30) 293.95 (187.55) 287.32 (172.96) 271.67 (133.03) 0.92 (0.99) 0.95 (0.92)
Ins120 (pmol/l)
¤ 5450 (4570/850/30) 207.13 (198.16) 210.64 (207.43) 188.53 (143.48) 0.55 (0.69) 0.52 (0.64)
AUCIns (pmol/l · min) 5045 (4227/791/27) 27795.2 (17784.9) 27412.34 (17018.2) 26148.89 (12052.43) 0.49 (0.90) 0.51 (0.93)
Indices of insulin secretion and beta-cell function
DI¤ 5031 (4216/788/27) 171.94 (73.12) 171.53 (72.63) 176.99 (86.879) 0.37 0.35
BIGTT-AIR 5030 (4215/788/27) 1916.03 (2484.30) 1823.89 (1038.50) 1718.15 (578.42) 0.57 (0.49) 0.58 (0.50)
CIR¤ 5270 (4408/832/30) 872.79 (729.90) 874.15 (731.58) 734.96 (443.06) 0.87 (0.87) 0.91 (0.83)
HOMA-B¤ 8927 (7489/1386/52) 63.75 (48.62) 61.75 (36.81) 62.66 (41.39) 0.96 (0.65) 0.93 (0.75)
AUCIns(0–30)/AUCGlu(0–30)
¤ 5174 (4331/814/29) 23.97 (13.84) 23.66 (13.11) 22.43 (8.91) 0.94 (0.97) 0.89 (0.94)
IGI¤ 5109 (4276/84/29) 104.38 (117.23) 108.27 (133.32) 81.24 (52.88) 0.67 (0.77) 0.58 (0.69)
AUCC-pep /AUCGlu
¤ 5480 (4597/854/29) 268.18 (79.58) 269.96 (81.90) 256.53 (61.19) 0.39 (0.55) 0.31(0.50)
Data are number of available samples (AA/AG/GG) with means (SD) according to genotype. Traits were tested for normality and log transformation was applied
(¤) where appropriate. P-values were adjusted for age, sex, BMI, and study group with values in parenthesis further adjusted for insulin sensitivity.
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fied during an infusion of a low dose of glucagon-like
peptide-1, which points to the possibility that the
incretin response following an oral glucose load may com-
pensate for any effect of the rs11085226 G-allele on
OGTT-derived measure of beta-cell function. In the
present study we did, however, not find an association of
the rs11085226 variant with the type 2 diabetic phenotype.
According to the database of genetic association studies
(available at www.gwascentral.com) the rs11085226 variant
has not been tested for association to T2D in individuals of
European ancestry, nor is it included in the stage 1 & 2
meta-analysis data of the DIAbetes Genetics Replication
And Meta-analysis (DIAGRAM) consortium (data avail-
able online at www.diagram-consortium.org) [11]. How-
ever, following the completion of our analyses, data from a
trans-ethnic meta-analysis including cohorts of individuals
with European, Mexican/Mexican American, south Asian
and east Asian ancestry became publically available [48],
including data on the rs11085226 variant showing no sig-
nificant association with T2D (OR = 1.01, 95CI: 0.94 - 1.07;
P = 0.85; N = 27767).
Given the limited number of studies included in the
meta-analysis, caution should be taken when assessingthese results, emphasized by the fact that a random ef-
fects analysis did not show a significant effect. It should
also be noted that assessment of population stratification
as a potential bias in the analyses of IVGTT traits was
not possible due to the lack of array based genotype
data. Yet, beta-cell responsiveness to glucose is a more
accurate measure of insulin release than traits derived
from levels of circulating insulin. Obtaining a significant
result, even if nominal only, despite the relatively small
number of subjects in the present study might
emphasize the importance of collecting refined traits
when assessing complex physiological processes such as
beta-cell function. Similarly, given the limited number of
subjects in the present study, it is possible that a small
effect of the rs11085226 variant on T2D susceptibility
remains undetected due to a lack of statistical power.
Furthermore, being a heterogeneous disorder poorly de-
fined by a dichotomized end-point, the variant may only
affect disease susceptibility in a subset of type 2 diabetic
patients.
Clearly the reported association does not hold for
stringent correction for 54 independent tests ad modum
Bonferroni. However, considering the correlation be-
tween the tested traits and the a priori knowledge of the
Table 3 Meta-analyses estimating the combined effect and 95% confidence interval of the minor allele of PTBP1 rs11085226 in the Family- and Youth92 study
(n = 596) assuming an additive and dominant model of inheritance
Additive inheritance Dominant inheritance
Fixed effect model Random effect model Fixed effect model Random effect model
Combined effect P Combined effect P Combined effect P Combined effect P
β-cell responsiveness to glucose (pmol · kg−1 · min−1/mmol · l) 0.054 (−0.097; 0.21) 0.5 0.038 (−0.23; 0.30) 0.8 −0.11 (−0.20; −0.025) 0.01 −0.13 (−0.25; 0.003) 0.06
Fasting ISR (pmol · kg−1 · min−1) 0.037 (−0.057; 0.13) 0.4 0.037 (−0.057; 0.13) 0.4 0.65 (−2.62; 3.92) 0.7 0.56 (−4.57; 5.69) 0.8
Disposition index* −0.11 (−0.302; 0.081) 0.25 0.51 (−0.99; 2.014) 0.5 −0.1030 (−0.299; 0.093) 0.3 0.51(−0.982; 2.011) 0.96
AUC ISR 0–8 min * (pmol · kg
−1) −0.0015 (−0.082; 0.079) 0.97 −0.0015 (−0.082; 0.079) 0.97 −0.060 (−0.16; 0.043) 0.3 −0.081 (−0.27; 0.11) 0.4
IncAUC ISR 0–8 min (pmol · kg
−1) 0.003 (−0.097; 0.10) 0.95 0.003 (−0.097; 0.10) 0.95 0.010 (−0.051; 0.072) 0.7 0.010 (−0.051; 0.072) 0.7
AUC insulin 0–8 min * (pmol/l · min) −0.043 (−0.15; 0.068) 0.4 −0.043 (−0.15; 0.068) 0.4 −0.094 (−0.29; 0.11) 0.4 −0.094 (−0.29; 0.11) 0.4
Acute phase insulin response (pmol/l · min) −85.40 (−381.20; 210.41) 0.6 −74.47 (−407.35; 258.41) 0.7 16.73 (−215.63; 249.09) 0.9 3.30 (−288.95; 295.55) 0.98
AUC glucose 0–8 min (mmol/l · min) 0.39 (−1.42; 2.20) 0.7 0.11 (−2.69; 2.91) 0.9 19.82 (−202.28; 241.92) 0.9 −5.020 (−338.55; 328.51) 0.98
IncAUC glucose 0–8 min (mmol/l · min) 0.36 (−1.2163; 1.9341) 0.66 0.35 (−1.27; 1.96) 0.7 0.02 (−1.42; 1.46) 0.98 0.16(−2.22; 2.55) 0.9
AUC C-peptide 0–8 min* (pmol/l · min) −0.0019 (−0.063; 0.059) 0.95 −0.0019 (−0.0632; 0.0594) 0.95 −0.0268 (−0.124; 0.0701) 0.6 −0.0336(−0.1582; 0.0910) 0.6
Acute phase C-peptide response (pmol/l · min) 7.69 (−582.011; 597.39) 0.98 10.081 (−586.71; 606.87) 0.97 176.92 (−357.81; 711.66) 0.5 176.92 (−357.81; 711.66) 0.5
Data is mean combined effect (95% CI) adjusted for age, sex, BMI, and insulin sensitivity (disposition index adjusted for age, sex, and BMI only). Estimates of traits displaying non-normality (*) were based on log
transformed values. Fixed effect model represent the combined effects of the studies weight using inverse variance. The Random effects model represent the combined effects of the studies weighted using the
DerSimonian-Laird method.
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Figure 1 Forest plot of meta-analysis estimating the combined effect of the G-allele of PTBP1 rs11085226 on beta-cell responsiveness
to glucose in the Youth92 and Family studies.
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Bonferroni correction might be overly conservative. Fur-
thermore, given that the association of the rs11085226
variant with beta-cell responsiveness to glucose has
not previously been reported, this part of the analysis
is exploratory and we therefore consider it relevant to
report significance at the nominal level only.
In the present study, as well as the previous study
by Heni and colleagues [9], the association of the
rs11085226 G-allele with reduced glucose-stimulated
insulin release was found under the assumption of a
dominant model of inheritance. PTBP1 exists in solu-
tion as a dimer [49], which could potentially explain
the genetic dominance. However, neither rs11085226
nor any of its five known proxies (rs10426084,
rs351977, rs10422347, rs10420407, and rs10420953 [in
LD with r2 > 0.8 as determined by the Broad Institute's
SNP Annotation and Proxy Search website using the
CEU panel from the 1000 genomes project pilot 1 and
HapMap release 22]), of which only rs10420953 is a
coding variant (N108N), results in any non-synonymous
amino acid substitutions in the PTBP1 protein. These are
however all common variants (MAF > 5%) and one could
speculate that the causal variant, which could very well be
coding, is rare and uncaptured by chip-based genotyping.
Furthermore, a reason why modelling the effect of the vari-
ant as additive does not reveal an association might the
low number of rare homozygous individuals in the IVGTT
cohorts, in which case an additive model does not give an
accurate representation of the data.Conclusion
Although failing to replicate the previously reported as-
sociation of PTBP1 rs11085226 to OGTT-derived mea
sures of beta-cell function, we show a nominal signifi-
cant association of the variant to reduced beta-cell re-
sponsiveness to glucose, a measure of glucose
stimulated insulin release not previously investigated
in relation to PTBP1. However, any effect the variant
may have on beta-cell function does not appear tohave a diabetogenic impact. Larger studies of IVGTT-
derived measures of dynamic beta-cell function or meta-
analysis thereof are needed to thoroughly investigate a
potential effect of the rs11085226 variant on glucose-
stimulated insulin release.
Additional file
Additional file 1: Supplementary tables and description of
methods.
Abbreviations
OGTT: Oral glucose tolerance test; IVGTT: Intravenous glucose tolerance test;
ISR: Insulin secretion rate; IGI: Insulinogenic index; IFG: Impaired fasting
glucose; AUC: Area under the curve; SNP: Single nucleotide polymorphism;
HOMA-B: Homeostatic model assessment of beta-cell function; HOMA-
IR: Homeostatic model assessment of insulin resistance; CIR: Corrected insulin
response; DI: Disposition index; MAF: Minor allele frequency;
PTBP1: Polypyrimidine tract binding protein 1; T2D: Type 2 Diabetes.
Competing interests
MEJ is employed by the Steno Diabetes Center A/S, which is a research and
teaching hospital collaborating with the Danish National Health Service and
owned by Novo Nordisk A/S. Additionally, TH, OP, and MEJ hold shares in
Novo Nordisk A/S. All other authors declare that there are no competing
interests associated with this manuscript.
Authors’ contributions
THH and APG conceived the study and performed the analyses, the
interpretation of results and the drafting of the manuscript. TJ, TL, MEJ, TH,
IB, CC and OP were involved in the initiation and collection of the study
populations. TH, HV and OP conceived the study, and participated in its
design and co-ordination and helped to draft the manuscript. All authors
have read and approved the final manuscript.
Acknowledgments
The authors would like to thank A. Forman, T. Lorentzen, B. Andersen, M.
Andersen, and G. Klavsen for technical assistance and A. Nielsen, P.
Sandbeck, and G. Lademann for managerial assistance.
This work was supported by research grants from The Novo Nordisk
Foundation Center for Basic Metabolic Research, an independent research
center at the University of Copenhagen partially funded by an unrestricted
donation from the Novo Nordisk Foundation (www.metabol.ku.dk), The
Lundbeck Foundation (www.lucamp.org), The Danish Agency for Science,
Technology and Innovation, the PhD School of Molecular Metabolism,
University of Southern Denmark, and the Copenhagen Graduate School of
Health and Medical Sciences. Funders had no influence on study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
The Inter99 study was initiated by T. Jørgensen (principal investigator), K.
Borch-Johnsen (co-principal investigator), H. Ibsen, and T.F. Thomsen. The
Hansen et al. BMC Medical Genetics  (2015) 16:17 Page 8 of 9steering committee comprises the former two and C. Pisinger. The Inter99
project was
financially supported by research grants from the Danish
Research Council, The Danish Centre for Health Technology Assessment,
Novo Nordisk, Research Foundation of Copenhagen County, Ministry of
Internal Affairs and Health, The Danish Heart Foundation, The Danish
Pharmaceutical Association, The Augustinus Foundation, The Ib Henriksen
Foundation, and the Becket Foundation.
The Health2006 and Health2010 studies were initiated by A. Linneberg
(principal investigator) and T. Jørgensen (co-principal investigator).
The ADDITION study was initiated by K. Borch-Johnsen (principal
investigator), T. Lauritzen (principal investigator), and A. Sandbæk. The study
was supported by the National Health Services in the counties of
Copenhagen, Aarhus, Ringkøbing, Ribe and South Jutland, together with the
Danish Research Foundation for General Practice, Danish Centre for
Evaluation and Health Technology Assessment, the diabetes fund of the
National Board of Health, the Danish Medical Research Council, the Aarhus
University Research Foundation and the Novo Nordisk Foundation. The study
received unrestricted grants from Novo Nordisk, Novo Nordisk Scandinavia,
Astra Denmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark, Servier
Denmark and HemoCue Denmark.
The study of the 1936 Birth cohort was initiated by H. Hollnagel and
continued by T. Jørgensen (principal investigator). The Danish Heart
Foundation and The Danish Medical Research Council financially supported
the 1996/97 investigation.
Author details
1The Novo Nordisk Foundation Center for Basic Metabolic Research, Section
of Metabolic Genetics, Faculty of Health and Medical Sciences, University of
Copenhagen, Universitetsparken 1, DK-2100 Copenhagen, Denmark.
2Research Centre for Prevention and Health, Glostrup University Hospital,
Nordre Ringvej 57, Building 84-85, DK-2600 Glostrup, Denmark. 3Faculty of
Health and Medical Sciences, University of Copenhagen, Copenhagen,
Denmark. 4Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte,
Denmark. 5Department of Public Health, Section of General Practice, Aarhus
University, Bartholins Allé 2, DK-8000 Aarhus, Denmark. 6Department of
Clinical Biochemistry, Vejle Hospital, Kabbeltoft 25, DK-7100 Vejle, Denmark.
7Institute of Regional Health Research, University of Southern Denmark,
Odense, Denmark. 8Department of Internal Medicine and Endocrinology, SLB,
Vejle Hospital, Kabbeltoft 25, DK-7100 Vejle, Denmark. 9Faculty of Health
Sciences, University of Southern Denmark, Odense, Denmark.
Received: 9 September 2014 Accepted: 26 February 2015
References
1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of
diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.
2. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of
pathogenesis and therapy. Lancet, 365(9467):1333–46.
3. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am.
2004;88(4):787–835.
4. Poulsen P, Kyvik KO, Vaag A, Beck-Nielsen H. Heritability of type II
(non-insulin-dependent) diabetes mellitus and abnormal glucose
tolerance–a population-based twin study. Diabetologia. 1999;42(2):139–45.
5. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes:
the Framingham Offspring Study. Diabetes. 2000;49(12):2201–7.
6. Pierce M, Keen H, Bradley C. Risk of diabetes in offspring of parents with
non-insulin-dependent diabetes. Diabet Med. 1995;12(1):6–13.
7. Grarup N, Sandholt C, Hansen T, Pedersen O. Genetic susceptibility to type
2 diabetes and obesity: from genome-wide association studies to rare
variants and beyond. Diabetologia. 2014;57(8):1528–41.
8. Drong AW, Lindgren CM, McCarthy MI. The genetic and epigenetic basis of
type 2 diabetes and obesity. Clin Pharmacol Ther. 2012;92(6):707–15.
9. Heni M, Ketterer C, Wagner R, Linder K, Böhm A, Herzberg-Schäfer SA, et al.
Polymorphism rs11085226 in the gene encoding polypyrimidine tract-
binding protein 1 negatively affects glucose-stimulated insulin secretion.
PLoS One. 2012;7(10):e46154.
10. Oh YL, Hahm B, Kim YK, Lee HK, Lee JW, Song O, et al. Determination of
functional domains in polypyrimidine-tract-binding protein. Biochem J.
1998;331(Pt 1):169–75.11. Spellman R, Rideau A, Matlin A, Gooding C, Robinson F, McGlincy N, et al.
Regulation of alternative splicing by PTB and associated factors. Biochem
Soc Trans. 2005;33(Pt 3):457–60.
12. Sawicka K, Bushell M, Spriggs Keith A, Willis Anne E. Polypyrimidine-tract-
binding protein: a multifunctional RNA-binding protein. Biochem Soc Trans.
2008;36(4):641.
13. Auweter SD, Allain FHT. Structure-function relationships of the
polypyrimidine tract binding protein. Cell Mol Life Sci. 2008;65(4):516–27.
14. Tillmar L, Control of Insulin mRNA Stability in Rat Pancreatic Islets.
Regulatory role of a 3’-untranslated region pyrimidine-rich sequence. J Biol
Chem. 2001;277(2):1099–106.
15. Knoch K-P, Bergert H, Borgonovo B, Saeger H-D, Altkrüger A, Verkade P,
et al. Polypyrimidine tract-binding protein promotes insulin secretory
granule biogenesis. Nat Cell Biol. 2004;6(3):8–214.
16. Knoch K-P, Meisterfeld R, Kersting S, Bergert H, Altkrüger A, Wegbrod C,
et al. cAMP-dependent phosphorylation of PTB1 promotes the expression
of insulin secretory granule proteins in β cells. Cell Metab. 2006;3(2):123–34.
17. Süss C, Czupalla C, Winter C, Pursche T, Knoch K-P, Schroeder M, et al. Rapid
Changes of mRNA-binding Protein Levels following Glucose and
3-Isobutyl-1-methylxanthine Stimulation of Insulinoma INS-1 Cells. Mol Cell
Proteomics. 2009;8(3):393–408.
18. Jang SK, Wimmer E. Cap-independent translation of encephalomyocarditis
virus RNA: structural elements of the internal ribosomal entry site and
involvement of a cellular 57-kD RNA-binding protein. Genes Dev. 1990;4
(9):1560–72.
19. Cote CA, Gautreau D, Denegre JM, Kress TL, Terry NA, Mowry KL. A xenopus
protein related to hnRNP I has a role in cytoplasmic RNA localization. Mol
Cell. 1999;4(3):431–7.
20. Song Y. Evidence for an RNA chaperone function of polypyrimidine
tract-binding protein in picornavirus translation. RNA. 2005;11(12):1809–24.
21. Fred RG, Bang-Berthelsen CH, Mandrup-Poulsen T, Grunnet LG, Welsh N.
High glucose suppresses human islet insulin biosynthesis by inducing
miR-133a leading to decreased polypyrimidine tract binding protein-
expression. PLoS One. 2010;5(5):e10843.
22. Ehehalt F, Knoch K, Erdmann K, Krautz C, Jäger M, Steffen A, et al. Impaired
insulin turnover in islets from type 2 diabetic patients. Islets. 2010;2(1):30–6.
23. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, et al.
Large-scale association analyses identify new loci influencing glycemic traits
and provide insight into the underlying biological pathways. Nat Genet.
2012;44(9):991–1005.
24. Gibbs RA, Belmont JW, Hardenbol P, Willis TD, Yu F, Yang H, et al. The
International HapMap Project. Nature. 2003;426(6968):789–96.
25. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes
mellitus and its complications. Part 1: diagnosis and classification of
diabetes mellitus provisional report of a WHO consultation. Diabet Med.
1998;15(7):539–53.
26. Glümer C, Jørgensen T, Borch-Johnsen K. Prevalences of diabetes and
impaired glucose regulation in a Danish population: the Inter99 study.
Diabetes Care. 2003;26(8):2335–40.
27. Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme
immunoassay for intact human insulin in serum or plasma. Clin Chem.
1993;39(4):578–82.
28. Heding LG. Specific and direct radioimmunoassay for human proinsulin in
serum. Diabetologia. 1977;13(5):467–74.
29. Faber OK, Markussen J, Naithani VK, Binder C. Production of antisera to
synthetic benzyloxycarbonyl-C-peptide of human proinsulin. Hoppe Seylers
Z Physiol Chem. 1976;357(6):751–7.
30. Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kuzuya H, et al.
Characterization of seven C-peptide antisera. Diabetes. 1978;27
Suppl 1:170–7.
31. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general
pedigrees. Am J Hum Genet. 1998;62(5):1198–211.
32. Phillips DIW, Clark PM, Hales CN, Osmond C. Understanding oral glucose
tolerance: comparison of glucose or insulin measurements during the oral
glucose tolerance test with specific measurements of insulin resistance and
insulin secretion. Diabet Med. 1994;11(3):286–92.
33. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H. Glucose tolerance and
insulin release, a mathematical approach I: assay of the beta-cell response
after oral glucose loading. Diabetes. 1976;25(4):241–4.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.
Homeostasis model assessment: insulin resistance and beta-cell function
Hansen et al. BMC Medical Genetics  (2015) 16:17 Page 9 of 9from fasting plasma glucose and insulin concentrations in man.
Diabetologia. 1985;28(7):412–9.
35. Hansen T, Drivsholm T, Urhammer SA, Palacios RT, Vølund A, Borch-Johnsen
K, et al. The BIGTT test: a novel test for simultaneous measurement of
pancreatic β-cell function, insulin sensitivity, and glucose tolerance.
Diabetes Care. 2007;30(2):257–62.
36. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin clamp.
Diabetes Care. 1999;22(9):1462–70.
37. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin
sensitivity and pancreatic responsivity from the frequently sampled
intravenous glucose tolerance test. Comput Methods Programs Biomed.
1986;23(2):113–22.
38. Steil GM, Volund A, Kahn SE, Bergman RN. Reduced sample number for
calculation of insulin sensitivity and glucose effectiveness from the minimal
model: suitability for use in population studies. Diabetes. 1993;42(2):250–6.
39. Steil GM, Murray J, Bergman RN, Buchanan TA. Repeatability of insulin
sensitivity and glucose effectiveness from the minimal model: implications
for study design. Diabetes. 1994;43(11):1365–71.
40. Ferrari P, Alleman Y, Shaw S, Riesen W, Weidmann P. Reproducibility of
insulin sensitivity measured by the minimal model method. Diabetologia.
1991;34(7):527–30.
41. Yang YJ, Youn JH, Bergman RN. Modified protocols improve insulin
sensitivity estimation using the minimal model. Am J Physiol.
1987;253(6 Pt 1):E595–602.
42. Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA. Measuring
prehepatic insulin secretion using a population model of C-peptide kinetics:
accuracy and required sampling schedule. Diabetologia. 1998;41(5):548–54.
43. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on
glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2
and nondiabetic subjects. Diabetes. 2003;52(2):380–6.
44. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors
controlling glucose tolerance in man: measurement of insulin sensitivity
and beta-cell glucose sensitivity from the response to intravenous glucose.
J Clin Invest. 1981;68(6):1456–67.
45. Bergman RN. Lilly lecture 1989: toward physiological understanding of
glucose tolerance: minimal-model approach. Diabetes. 1989;38(12):1512–27.
46. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials.
1986;7(3):177–88.
47. Prokopenko I, Poon W, Mägi R, Prasad BR, Salehi SA, Almgren P, et al. A
central role for GRB10 in regulation of islet function in man. PLoS Genet.
2014;10(4):e1004235.
48. Replication DIG, Meta-analysis C, Asian Genetic Epidemiology Network Type
2 Diabetes C, South Asian Type 2 Diabetes C, Mexican American Type 2
Diabetes C, Type 2 Diabetes Genetic Exploration by Next-generation
sequencing in multi-Ethnic Samples C, Mahajan A, Go MJ, Zhang W, Below
JE, et al. Genome-wide trans-ancestry meta-analysis provides insight into
the genetic architecture of type 2 diabetes susceptibility. Nat Genet.
2014;46(3):234–44.
49. Pérez I, McAfee JG, Patton JG. Multiple RRMs contribute to RNA binding
specificity and affinity for polypyrimidine tract binding protein†.
Biochemistry. 1997;36(39):11881–90.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
